{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T09:37:53Z","timestamp":1770716273553,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23H00458"],"award-info":[{"award-number":["23H00458"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04621-7","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:05:36Z","timestamp":1768219536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term safety and treatment discontinuation patterns of OnabotulinumtoxinA for post-stroke spasticity: a retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Ken","family":"Azuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiyuki","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Kamimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiko","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"issue":"3 Suppl 2","key":"4621_CR1","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1212\/WNL.0b013e3182762448","volume":"80","author":"J Wissel","year":"2013","unstructured":"Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology. 2013;80(3 Suppl 2):S13\u20139. https:\/\/doi.org\/10.1212\/WNL.0b013e3182762448.","journal-title":"Neurology"},{"issue":"14","key":"4621_CR2","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/09638288.2016.1198432","volume":"39","author":"M Barnes","year":"2017","unstructured":"Barnes M, Kocer S, Murie Fernandez M, Balcaitiene J, Fheodoroff K. An international survey of patients living with spasticity. Disabil Rehabil. 2017;39(14):1428\u201334. https:\/\/doi.org\/10.1080\/09638288.2016.1198432.","journal-title":"Disabil Rehabil"},{"issue":"14","key":"4621_CR3","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.clinthera.2011.01.005","volume":"32","author":"EL Olvey","year":"2010","unstructured":"Olvey EL, Armstrong EP, Grizzle AJ. Contemporary pharmacologic treatments for spasticity of the upper limb after stroke: a systematic review. Clin Ther. 2010;32(14):2282\u2013303. https:\/\/doi.org\/10.1016\/j.clinthera.2011.01.005.","journal-title":"Clin Ther"},{"issue":"2","key":"4621_CR4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.23736\/S1973-9087.16.04329-X","volume":"53","author":"Y Dong","year":"2017","unstructured":"Dong Y, Wu T, Hu X, Wang T. Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis. Eur J Phys Rehabil Med. 2017;53(2):256\u201367. https:\/\/doi.org\/10.23736\/S1973-9087.16.04329-X.","journal-title":"Eur J Phys Rehabil Med"},{"issue":"6","key":"4621_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/mds.22452","volume":"24","author":"AE Elia","year":"2009","unstructured":"Elia AE, Filippini G, Calandrella D, Albanese A. Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord. 2009;24(6):801\u201312. https:\/\/doi.org\/10.1002\/mds.22452.","journal-title":"Mov Disord"},{"issue":"5","key":"4621_CR6","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.apmr.2012.12.006","volume":"94","author":"N Foley","year":"2013","unstructured":"Foley N, Pereira S, Salter K, Fernandez MM, Speechley M, Sequeira K, et al. Treatment with botulinum toxin improves upper-extremity function post stroke: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2013;94(5):977\u201389. https:\/\/doi.org\/10.1016\/j.apmr.2012.12.006.","journal-title":"Arch Phys Med Rehabil"},{"key":"4621_CR7","doi-asserted-by":"crossref","unstructured":"Sun L-C et al. Efficacy and Safety of Botulinum Toxin Type A for Limb Spasticity after Stroke: A Meta-Analysis of Randomized Controlled Trials. BioMed Research International 2019, 1\u201317 (2019).","DOI":"10.1155\/2019\/8329306"},{"issue":"10","key":"4621_CR8","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/ptj\/84.10.973","volume":"84","author":"JE Gallichio","year":"2004","unstructured":"Gallichio JE. Pharmacologic management of spasticity following stroke. Phys Ther. 2004;84(10):973\u201381.","journal-title":"Phys Ther"},{"issue":"6","key":"4621_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.2340\/16501977-1817","volume":"46","author":"AB Ward","year":"2014","unstructured":"Ward AB, Wissel J, Borg J, Ertzgaard P, Herrmann C, Kulkarni J, et al. Functional goal achievement in post-stroke spasticity patients: the BOTOX\u00ae economic spasticity trial (BEST). J Rehabil Med. 2014;46(6):504\u201313. https:\/\/doi.org\/10.2340\/16501977-1817.","journal-title":"J Rehabil Med"},{"issue":"11","key":"4621_CR10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/pmrj.12328","volume":"12","author":"GE Francisco","year":"2020","unstructured":"Francisco GE, Jost WH, Bavikatte G, Bandari DS, Tang SF, Munin MC, et al. Individualized OnabotulinumtoxinA treatment for upper limb spasticity resulted in high clinician- and patient-reported satisfaction: long-term observational results from the ASPIRE study. PM R. 2020;12(11):1120\u201333. https:\/\/doi.org\/10.1002\/pmrj.12328.","journal-title":"PM R"},{"issue":"1","key":"4621_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s12325-018-0833-7","volume":"36","author":"C Marciniak","year":"2019","unstructured":"Marciniak C, Munin MC, Brashear A, Gordon MF, Do M, Cloud LJ, et al. IncobotulinumtoxinA efficacy and safety in adults with upper-limb spasticity following stroke: results from the open-label extension period of a phase 3 study. Adv Ther. 2019;36(1):187\u201399. https:\/\/doi.org\/10.1007\/s12325-018-0833-7.","journal-title":"Adv Ther"},{"issue":"7","key":"4621_CR12","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s00415-020-09777-5","volume":"267","author":"Y Masakado","year":"2020","unstructured":"Masakado Y, Abo M, Kondo K, Saeki S, Saitoh E, Dekundy A, et al. Efficacy and safety of incobotulinumtoxinA in post-stroke upper-limb spasticity in Japanese subjects: results from a randomized, double-blind, placebo-controlled study (J-PURE). J Neurol. 2020;267(7):2029\u201341. https:\/\/doi.org\/10.1007\/s00415-020-09777-5.","journal-title":"J Neurol"},{"key":"4621_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jns.2017.04.052","volume":"378","author":"A Santamato","year":"2017","unstructured":"Santamato A, Panza F, Intiso D, Baricich A, Picelli A, Smania N, et al. Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke. J Neurol Sci. 2017;378:182\u20136. https:\/\/doi.org\/10.1016\/j.jns.2017.04.052.","journal-title":"J Neurol Sci"},{"key":"4621_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/toxins16090383","volume":"16","author":"N Falcone","year":"2024","unstructured":"Falcone N, Leo F, Chisari C, Dalise S. Long-term management of post-stroke spasticity with botulinum toxin: a retrospective study. Toxins. 2024;16:383.","journal-title":"Toxins"},{"key":"4621_CR15","doi-asserted-by":"publisher","unstructured":"Battaglia M. Post-stroke spasticity: follow-up and functional implications of chronic long-term treatment with botulinum toxin.\u00a0Eur J Phys Rehabil Med. 2024;60.https:\/\/doi.org\/10.1002\/acn3.51225","DOI":"10.1002\/acn3.51225"},{"issue":"1","key":"4621_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/acn3.51225","volume":"8","author":"JI Lee","year":"2021","unstructured":"Lee JI, Jansen A, Samadzadeh S, Kahlen U, Moll M, Ringelstein M. Long-term adherence and response to botulinum toxin in different indications. Ann Clin Transl Neurol. 2021;8(1):15\u201328. https:\/\/doi.org\/10.1002\/acn3.51225.","journal-title":"Ann Clin Transl Neurol."},{"issue":"10","key":"4621_CR17","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s10072-017-3078-3","volume":"38","author":"P Latino","year":"2017","unstructured":"Latino P, Castelli L, Prosperini L, Marchetti MR, Pozzilli C, Giovannelli M. Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study. Neurol Sci. 2017;38(10):1841\u20138. https:\/\/doi.org\/10.1007\/s10072-017-3078-3.","journal-title":"Neurol Sci"},{"issue":"4","key":"4621_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.rehab.2019.06.003","volume":"62","author":"P Marque","year":"2019","unstructured":"Marque P, Denis A, Gasq D, Chaleat-Valayer E, Yelnik A, Colin C, et al. Botuloscope: 1-year follow-up of upper limb post-stroke spasticity treated with botulinum toxin. Ann Phys Rehabil Med. 2019;62(4):207\u201313. https:\/\/doi.org\/10.1016\/j.rehab.2019.06.003.","journal-title":"Ann Phys Rehabil Med"},{"key":"4621_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14100675","volume":"14","author":"N Cinone","year":"2022","unstructured":"Cinone N, et al. Reasons and determinants of BoNT-A treatment discontinuation in patients living with spasticity: a 10-year retrospective analysis. Toxins. 2022;14:675.","journal-title":"Toxins"},{"key":"4621_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/toxins17030103","volume":"17","author":"E Leblong","year":"2025","unstructured":"Leblong E, et al. Switox: retrospective analysis of botulinum toxin switching in management of spasticity. Toxins. 2025;17:103.","journal-title":"Toxins"},{"key":"4621_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/toxins17030102","volume":"17","author":"E Cecchella","year":"2025","unstructured":"Cecchella E, et al. Barriers to Long-Term adherence in botulinum toxin therapy for Post-Stroke spasticity: insights and implications from a Single-Center study in North Italy. Toxins. 2025;17:102.","journal-title":"Toxins"},{"key":"4621_CR22","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2490\/jjrmc.47.714","volume":"47","author":"A Kimura","year":"2010","unstructured":"Kimura A, Abo M, Kawate N, Osako Y, Suyama K, Maeda T, et al. Efficacy and safety of botulinum toxin type A in treating upper limb spasticity in post-stroke patients: a multicenter, double-blind, placebo-controlled trial followed by an open-label trial. Jpn J Rehabil Med. 2010;47:714\u201327.","journal-title":"Jpn J Rehabil Med"},{"issue":"1","key":"4621_CR23","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1212\/WNL.0000000000006688","volume":"92","author":"P Albrecht","year":"2019","unstructured":"Albrecht P, Jansen A, Lee JI, Moll M, Ringelstein M, Rosenthal D, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2019;92(1):e48\u201354. https:\/\/doi.org\/10.1212\/WNL.0000000000006688.","journal-title":"Neurology"},{"issue":"2","key":"4621_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","volume":"120","author":"M Naumann","year":"2013","unstructured":"Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm. 2013;120(2):275\u201390. https:\/\/doi.org\/10.1007\/s00702-012-0893-9.","journal-title":"J Neural Transm"},{"issue":"1","key":"4621_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H G\u00f6schel","year":"1997","unstructured":"G\u00f6schel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies\u2013therapeutic consequences. Exp Neurol. 1997;147(1):96\u2013102. https:\/\/doi.org\/10.1006\/exnr.1997.6580.","journal-title":"Exp Neurol"},{"issue":"8","key":"4621_CR26","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.apmr.2014.04.011","volume":"95","author":"A Picelli","year":"2014","unstructured":"Picelli A, Tamburin S, Cavazza S, Scampoli C, Manca M, Cosma M, et al. Relationship between ultrasonographic, electromyographic, and clinical parameters in adult stroke patients with spastic equinus: an observational study. Arch Phys Med Rehabil. 2014;95(8):1564\u201370. https:\/\/doi.org\/10.1016\/j.apmr.2014.04.011.","journal-title":"Arch Phys Med Rehabil"},{"issue":"7","key":"4621_CR27","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.apmr.2012.02.005","volume":"93","author":"A Picelli","year":"2012","unstructured":"Picelli A, Bonetti P, Fontana C, Barausse M, Dambruoso F, Gajofatto F, et al. Is spastic muscle echo intensity related to the response to botulinum toxin type A in patients with stroke? A cohort study. Arch Phys Med Rehabil. 2012;93(7):1253\u20138. https:\/\/doi.org\/10.1016\/j.apmr.2012.02.005.","journal-title":"Arch Phys Med Rehabil"},{"issue":"6","key":"4621_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.rehab.2018.04.004","volume":"62","author":"KS Sunnerhagen","year":"2019","unstructured":"Sunnerhagen KS, Opheim A, Alt Murphy M. Onset, time course and prediction of spasticity after stroke or traumatic brain injury. Ann Phys Rehabil Med. 2019;62(6):431\u20134. https:\/\/doi.org\/10.1016\/j.rehab.2018.04.004.","journal-title":"Ann Phys Rehabil Med"},{"key":"4621_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.33393\/dti.2021.2342","volume":"15","author":"S Losi","year":"2021","unstructured":"Losi S, Berra CCF, Fornengo R, Pitocco D, Biricolti G, Federici MO. The role of patient preferences in adherence to treatment in chronic disease: a narrative review. Drug Target Insights. 2021;15:13\u201320. https:\/\/doi.org\/10.33393\/dti.2021.2342.","journal-title":"Drug Target Insights"},{"issue":"5","key":"4621_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3390\/toxins12050315","volume":"12","author":"D Intiso","year":"2020","unstructured":"Intiso D, Simone V, Bartolo M, Santamato A, Ranieri M, Gatta MT, et al. High dosage of botulinum toxin type A in adult subjects with spasticity following acquired central nervous system damage: where are we at? Toxins (Basel). 2020;12(5):315. https:\/\/doi.org\/10.3390\/toxins12050315.","journal-title":"Toxins (Basel)"},{"key":"4621_CR31","unstructured":"Ghandili M, Dhaliwal JS, Neuroanatomy. Putamen. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan\u2013 [Updated 2023 Aug 11]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK542184\/"},{"key":"4621_CR32","unstructured":"Torrico TJ, Mishra A, Dominguez JF, Neuroanatomy. Thalamus. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan\u2013 [Updated 2023 Jul 23]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK542170\/"},{"key":"4621_CR33","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/svn-2024-003418","volume":"10","author":"X Yuan","year":"2025","unstructured":"Yuan X, et al. Central post-stroke pain: advances in clinical and preclinical research. Stroke Vasc Neurol. 2025;10:391\u2013406.","journal-title":"Stroke Vasc Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04621-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04621-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04621-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:26:39Z","timestamp":1770643599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-025-04621-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4621"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04621-7","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Keio University Hospital (Approval No. 20231066). Informed consent was obtained from all participants via an opt-out procedure described on the institutional website. All procedures were conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Michiyuki Kawakami has served as a speaker for GlaxoSmithKline and Teijin Healthcare and received honoraria for lectures on botulinum toxin therapy.Yuka Yamada has received payments for lectures from Teijin Pharma Ltd and Ishiyaku Publishers, Inc. All other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}